Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics, Genecast Biotechnology Ink Worldwide Research Services Agreement

NEW YORK – Interpace Diagnostics said today that its subsidiary Interpace BioPharma has partnered with Beijing, China-based Genecast Biotechnology to jointly develop, promote, and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies.  

As part of the collaboration, Parsippany, New Jersey-based Interpace will perform services worldwide except in China, where Genecast will provide services. 

"This collaboration is in line with our business strategy of driving sustainable, long-term growth and profitability by leveraging our unique capabilities," Michael McCartney, Interpace Biopharma chief commercial officer, said in a statement. 

Financial details of the agreement were not disclosed. 

"This partnership with Interpace will strengthen our capabilities to provide our customers with high-quality, streamlined one-stop testing services globally and is in line with our strategy of helping pharmaceutical and biotech companies to accelerate their biomarker-driven drug development and drive precision medicine forward," Genecast CEO and Cofounder Du Bo said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more